Tumor Mutational Burden Analysis
A TMB assay utilizing a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across various tumor indications
Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio and is available for RUO or GCP applications.
Highlights:
- TMB assay available in two formats: tumor-only specimens or matched tumor and germline control blood specimens.
- Based on validated WES assay targeting ~60Mb of coding region of the human genome.
- TMB tumor-only WES method modeled across multiple tumor indications.
- High quantitative precision (CV% ≤20%) for TMB >2, suitable for TMB analysis across a wide range of cancer indications including those with traditionally low TMB.
IQVIA Laboratories TMB (WES)1 |
1.5 (N=123) |
2.4 (N=38) |
2.4 (N=100) |
4.6 (N=64) |
8.7 (N=39) |
10.1 (N=258) |
13.2 (N=113) |
Published TMB2 | 1.8 (N=220) |
2.5 (N=1456) |
2.7 (N=543) |
4.5 (N=7758) |
7.2 (N=80) |
9 (N=2102) |
14.4 (N=879) |
1 Median TMB scores generated from TCGA whole exome sequencing reads through our pipeline
2 Median TMB scores per Chalmers et al., Genome Medicine 2017
3 https://gdc.cancer.gov/about-data /publications/mc3-2017
LGG=Lower Grade Glioma, CHOL=Cholangiocarcinoma, KIRC=Renal Clear Cell Carcinoma, COAD=Colon Adenocarcinoma, BLCA=Urothelial Carcinoma, LUSC=Lung Squamous Cell Carcinoma,
SKCM=Cutaneous Melanoma, BRCA=Breast Invasive Carcinoma, HNSC=Head-Neck Squamous Cell Carcinoma, LUAD=Lung Adenocarcinoma, SKCM=Cutaneous Melanoma; STAD=Stomach Adenocarcinoma
TMB assay specifications |
|
---|---|
Sample Types | Tumor tissue (FFPE, fresh frozen or DNA specimens) Normal tissue, optional (PBMC, whole blood or DNA |
DNA Requirements | 250 ng DNA |
Assay Method | Whole Exome Sequencing |
System Compatibility | NovaSeq 6000, HiSeq 2500 |
Assay Performance | >99.9% accuracy of variant calling for variants above 10% allelic frequency Quantitative precision ≤20% CV% across TMB range of 2-32 |
Deliverables | TMB score, FASTQ, BAM, annotated VCF files |
Immuno Assay Portfolio
Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio
Related Services
Clinical Genomics Laboratory Services
Learn moreNext Generation Sequencing Services
Learn moreMicrosatellite Instability (MSI) Assay
Learn moreImmune Landscape Signatures
Learn moreTruSight Oncology 500 Plasma Assay
Learn moreRNA Sequencing and DNA Sequencing Services
Learn moreBiomarker Services
Learn moreBioinformatics
Learn moreCentral Laboratory Services
Learn moreRelated Insights
Reproducibility Challenges in an era of Massive Data
Presented at the MCBIOS & MAQC 2021 Joint Conference
A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency
Presented at the MCBIOS & MAQC 2021 Joint Conference
Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing
Presented at the MCBIOS & MAQC 2021 Joint Conference
Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy
Gene expression and analysis for detection of 38 Immune Landscape Signatures
Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials
Genomic technologies that empower and enhance immuno-oncology trials
Laboratory Solutions for Hepatitis B (HBV) Clinical Trials
Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases
Enabling blood sample prep for single cell sequencing in clinical research
The Role of Genomics in Clinical Trials with Patrick Hurban
I-O clinical development podcast series
IQVIA Laboratories Corporate Brochure
Learn about what we do and our commitment to innovation
Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use
AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention